Emergent Biosolutions Inc (EBS) stock news · rev $742.9M
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
This EBS news page leads with what Emergent Biosolutions Inc filed — not a scraped headline mill.
No cached 8-K sentence for EBS yet. We will not pad this page with generic market recap.
Latest reported EBS revenue for 2025-12-31 was $742.9M. Net income was $52.6M. Revenue was down 28.8% from 2024-12-31 to 2025-12-31. EBS currently screens at market cap $416.4M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the EBS stock page; for the tape open the quote page.
EBS stock news FAQ
What are EBS's latest revenue and net income?
Latest cached Emergent Biosolutions Inc (EBS) revenue for Dec 31, 2025 was $742.9M. Net income was $52.6M. Statements: https://lician.com/financials/ebs
How did EBS revenue change from the prior cached period?
Cached Emergent Biosolutions Inc (EBS) revenue was down 28.8% from $1.04B (Dec 31, 2024) to $742.9M (Dec 31, 2025). Statements: https://lician.com/financials/ebs
What is EBS's market cap?
Emergent Biosolutions Inc (EBS) market cap is $416.4M on the latest cached fundamentals snapshot.
What kind of company is EBS?
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Where is EBS stock news listed?
Cached stock news for Emergent Biosolutions Inc (EBS) is listed at https://lician.com/news/ebs. Filings: https://lician.com/sec/ebs
Not investment advice.